Byetta · Bydureon
Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally isolated from the saliva of the Gila monster lizard (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA (2005) for the treatment of type 2 diabetes mellitus. Exenatide shares approximately 53% sequence homology with human GLP-1 but is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), giving it a clinically useful duration of action.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Potently activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells and suppressing inappropriate postprandial glucagon secretion from alpha cells. The glucose-dependent mechanism reduces hypoglycemia risk.
Significantly slows gastric emptying (especially the immediate-release formulation), reducing the rate of glucose appearance in the bloodstream after meals and contributing to satiety and reduced food intake.
Acts on hypothalamic appetite-regulating centers to promote satiety and reduce caloric intake, contributing to the modest weight loss observed with treatment.
Days 1-14: Immediate postprandial glucose improvement (Byetta). GI side effects peak and begin to subside. Appetite reduction noticeable.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Exenatide 5 mcg twice daily for four weeks followed by 10 mcg supports Byetta titration.
Patients received exenatide 5 microg twice-daily for 4 weeks followed by 10 microg for 26 weeks.
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Evidence scope. Human type 2 diabetes; route not explicit in this sentence.
Extended-release exenatide 2 mg SubQ once weekly matches Bydureon quick start.
We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly.
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Evidence scope. Human type 2 diabetes; extended-release SubQ formulation.
Exenatide increases glucose-dependent insulin, suppresses glucagon, slows gastric emptying, and reduces food intake.
Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of beta-cell mass in rodent studies and weight loss and inhibition of food intake in humans.
Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.
Evidence scope. Review; separates rodent beta-cell evidence from human food-intake effects.
Nausea, vomiting, and diarrhea were more common with twice-daily exenatide than insulin glargine.
Gastrointestinal symptoms were more common in the exenatide group than in the insulin glargine group, including nausea (57.1% vs. 8.6%), vomiting (17.4% vs. 3.7%) and diarrhea (8.5% vs. 3.0%).
Evidence scope. Human type 2 diabetes; exenatide 10 mcg twice daily.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Pancreatitis causality. No checked abstract established causality at the displayed regimens.
Oral-contraceptive warning attached to exenatide. The card itself attributes the FDA warning to tirzepatide; no exenatide abstract supported transfer.
(Byetta immediate-release). Bydureon extended-release provides sustained levels over 7 days from microsphere depot.
SubQ (Byetta), ~2 weeks SubQ (Bydureon steady state at week 6-7)
(Byetta), ~10 weeks to clear (Bydureon depot)
SubQ
Byetta: 6-10 hours (covers 1 meal per dose); Bydureon: 7 days (sustained GLP-1 receptor activation from microsphere depot)
Renal (glomerular filtration and proteolytic degradation in the kidney); DPP-4 resistant
Storage. Byetta: Store refrigerated at 2-8C. After first use, may be kept at room temperature (up to 25C) for up to 30 days. Bydureon: Store refrigerated. Protect from light.
FDA-approved. Byetta (exenatide immediate-release) approved 2005 for type 2 diabetes. Bydureon (exenatide extended-release) approved 2012. Also EMA-approved. Marketed by AstraZeneca. Prescription drug in all markets.
Put it to work
Open Exenatide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Exenatide in the app →Go deeper
The complete Exenatide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.